diabetes

Promising follow-up data from TN-10 teplizumab study published in Science Translational Medicine

Topline data from a recent Eli Lilly clinical trial indicate that tirzepatide led to superior A1C and body weight reductions from baseline compared to injectable semaglutide in adults with type 2 diabetes.

University of Arizona researcher looks beyond traditional causes to find novel therapies

Eli Lilly's glucagon-like peptide-1 receptor agonist reduced A1C and body weight in adults with type 2 diabetes in Phase 3 SURPASS trials

Researchers publish new data on the enzyme glyoxalase II and its role in cellular metabolism